Skip to main content

Table 4 Baseline characteristics of patients having Dobutamine Stress Echocardiography

From: Assessing cardiovascular risk in chronic kidney disease patients prior to kidney transplantation: clinical usefulness of a standardised cardiovascular assessment protocol

 

DSE positive

DSE negative

 

Number

34

81

 

Age

59.4 ± 8.2

58.8 ± 10.6

p = 0.736

Male

20 (58.8%)

46 (56.8%)

p = 0.841

Body Mass Index (Kg/m2)

28.2 ± 6.0

28.1 ± 4.1

p = 0.902

Cholesterol (mmol/L)

4.10 ± 1.16

4.28 ± 1.24

p = 0.491

High Density Lipoprotein (mmol/L)

1.21 ± 0.50

1.24 ± 0.43

p = 0.804

Triglycerides (mmol/L)

1.75 ± 1.00

1.51 ± 0.69

p = 0.179

Parathyroid Hormone Level (pmol/L)

31.6 ± 36.3

43.3 ± 52.3

p = 0.180

C-Reactive Protein (mg/L)

9.9 ± 12.0

9.4 ± 16.1

p = 0.867

Haemoglobin (g/L)

107.8 ± 15.3

107.8 ± 17.0

p = 0.998

Ferritin (μg/L)

292.6 ± 225.2

321.0 ± 329.4

p = 0.652

Modality

p = 0.313

 Haemodialysis

14 (41.2%)

26 (32.1%)

 

 Peritoneal Dialysis

2 (5.9%)

1 (1.2%)

 Kidney Transplant

2 (5.9%)

9 (11.1%)

 No Renal Replacement Therapy

16 (47.1%)

45 (55.6%)

 Diabetes

24 (70.6%)

33 (40.7%)

p = 0.003

 Hypertension

33 (97.1%)

77 (95.1%)

p = 0.632

 Ischaemic Heart Disease

9 (26.5%)

7 (8.6%)

p = 0.012

 Ever smoked

12 (35.3%)

35 (43.2%)

p = 0.594

 Peripheral Vascular Disease

2 (5.9%)

2 (2.5%)

p = 0.362

 Cerebrovascular Accident/TIA

4 (11.8%)

7 (8.6%)

p = 0.603

 Congestive Cardiac Failure

1 (2.9%)

0 (0%)

p = 0.121

Medication

 ACEi/ARB

17 (50.0%)

39 (48.1%)

p = 0.856

 Antiplatelet

19 (55.9%)

25 (30.9%)

p = 0.012

 Beta-Blocker

15 (44.1%)

26 (32.1%)

p = 0.219

 Statin

23 (67.6%)

36 (44.4%)

p = 0.023

 High Cardiovascular Risk

31 (91.2%)

72 (88.9%)

p = 0.714

  1. Results are expressed as mean ± standard deviation or number and percentage (%) where indicated. DSE Dobutamine Stress Echocardiography, ACEi Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin II Receptor Blocker, Statin HMG CoA Reductase Inhibitor